Dosimetric Comparison between Magnetic Resonance Imaging-Guided Plan and Point A-based Dose Prescrip

来源 :西部放射治疗协会妇科肿瘤放疗第一届第二次大会暨2015年妇科肿瘤放射治疗新进展学术研讨会 | 被引量 : 0次 | 上传用户:lw8312188
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Purpose:The purpose of this study was to comprehensively compare the 3-dimensional(3D)magnetic resonance imaging(MRI)-guided intracavitary brachytherapy(BT)and conventional 2-dimensional(2D)point A-based intracavitary BT planning for cervical cancer with regard to target coverage and doses to adjacent organs-at risk(OARs).Methods:A total of 79 consecutive patients with cervical cancer were first treated with 2D point A-based external beam radiation therapy,and then with high-dose-rate(HDR)BT between October 2011 and April 2013 at the First Hospital Affiliated to Xian Jiao Tong University,Xian,China.The 2D and 3D treatment planning were compared the difference of the target coverage and doses to bladder,rectum and sigmoid colon.Results:In small tumors,3D BT planning resulted in significantly higher doses to target but lower doses to OARs compared with 2D planning(P<0.05).In big and eccentric tumors,doses to tumor target and OARs in 3D planning were all significantly higher than in 2D planning(P<0.05).However,for the eccentric small tumors,volume doses to OARs in 3D planning were significantly lower than in 2D planning(P<0.05).For bladder and ureter tissues invaded by tumors,the doses to target in 3D planning were significantly higher than in 2D planning(P<0.05).In 3D planning,the doses to adjacent rectum and bladder were significantly higher but those to sigmoid colon were lower than in 2D planning(P<0.05).Conclusions:3D MRI image-guided BT planning increases the dose coverage of target and reduces the HDR-BT-induced toxicity to OARs.
其他文献
目的:探讨腓骨截骨术为主综合治疗膝内侧间室型骨性关节炎的32例临床报告,旨在提高腓骨截骨术治疗膝骨性关节炎的临床效果.方法:本组32例病例中,22例采取了腓骨截骨术结合关节内腔内注射SA(美丹特),8例合并严重的关节积液,结合关节腔灌洗及关节内注射rhTNFR:Fc(重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白),5例合并游离体配合了关节镜灌洗及清理术,15例严重膝内翻配合了支具疗法等.结果:疗效判定
目的:研究一种新型抗胃泌素17疫苗的体液免疫原性与抗原性.方法:疫苗以方案(0.5mg·只-1×免疫1次.2周-1×免疫3次,i.m)对新西兰大白兔(雌性,n=6)进行免疫,以酶联免疫吸附实验(en-zyme-linked immunosorbent assay,ELISA)检测免疫开始后第4、6、8周动物血清内IgG抗体滴度;以竞争性ELISA法检测各类人源蛋白[酰胺化胃泌素17(amidate
目的:原核表达脑膜炎球菌表面蛋白fHBP,研究其免疫原性.方法:筛选A和B两个亚家族的fHBP基因序列分别克隆至质粒pET-24b(+)和pET-28a(+),构建重组表达质粒pET-28a-/HBP-A和pET-24b fHBP-B.转化感受态细胞E.coli BL21(DE3),IPTG诱导表达.表达蛋白经镍柱亲和层析和凝胶过滤层析后免疫家兔,制备多克隆抗体.采用流式细胞术、血清杀菌力试验和被
单独使用狂犬病疫苗无法对暴露后人群进行全面有效的保护,常导致免疫失败,原因在于现有疫苗产生中和抗体较慢且难以诱导细胞免疫.因此,亟需开发更加安全有效的狂犬病疫苗.在本研究中,将皮卡佐剂引入狂犬病疫苗,成功制备了皮卡狂犬病疫苗.皮卡佐剂作为一种生化合成的双链RNA类似物,是TLR3的激动剂.试验结果显示,皮卡狂犬病疫苗能够增强动物机体的体液免疫和细胞免疫应答,且皮卡狂犬病疫苗对病毒暴露后免疫的保护率
目的:对复制缺陷型天坛株天花疫苗的安全性和免疫原性进行评估.方法:使用复制缺陷型天坛株天花疫苗分别对小鼠和乳鼠进行脑内注射,对青紫蓝家兔进行皮内注射,与复制型天坛株天花疫苗作为对照,检验其毒力;使用复制缺陷型天坛株天花疫苗分别对小鼠和青紫蓝家兔进行两次肌肉注射,并取血清检测中和抗体和Elisa抗体水平.结果:与复制型天坛株天花疫苗相比,复制缺陷型天坛株天花疫苗的小鼠和乳鼠脑内毒力及家兔皮肤毒力均明
目的:确定HSV1候选亚单位疫苗gD蛋白(gD1)的最佳配伍佐剂、免疫剂量以及免疫程序.方法:使用不同佐剂(PBS、Alum、Poly I:C及Alum&Poly I:C)配伍不同剂量的gD1蛋白(2μg、10μg、30μg/只),制成12种注射制剂,后肢肌肉注射免疫随机分组的12组BALB/c小鼠,初次免疫后于第14、35天各加强免疫一次,每次免疫前及末次免疫后两周眼眶静脉窦取血,分离血清后使用
目的:在原核细胞中表达埃可病毒6型的表面蛋白VP1,制备其多克隆抗体.方法:筛选VP1抗原表位富集区,优化基因序列,分别克隆至质粒pGEX-4T-2和pET-28a(+)中,构建重组表达质粒pGEX-4T-2-vp1和pET-28a-vp1,分别转化大肠杆菌(E.coli)BL21(DE3),经IPTG诱导表达后,分别用High AffinityGST-NTA resin和High Affinit
目的:建立SFTSV抗原(糖蛋白)的定量检测方法,用于疫苗生产过程中SFTSV抗原含量的监测.方法:用SFTSV抗原分别免疫新西兰兔及BALB/c小鼠,制备抗SFTSV多克隆抗体和单克隆抗体.采用抗SFTSV多克隆抗体作为包被抗体、经HRP标记的单克隆抗体作为酶标抗体,构建SFTSV抗原定量检测的双抗体夹心ELISA方法,确定该方法的线性范围、灵敏度,并对该方法的准确性、精密性、专属性进行验证.结
背景:发热伴血小板减少综合征(severe fever with thrombocytopenia syndrome,SFTS)是一种新发病毒传染性疾病,其病原发热伴血小板减少综合征布尼亚病毒(severe fever with thrombocytopenia syn-drome bunyavlrus,SFTSV)在2010年被分离并首次报道.目前没有针对该疾病的特异性治疗方法,加快研制安全有效
目的:以不同浓度的HBsAg血浆样品,分别对7种HBsAg定量检测试剂的检测范围、定量准确性及对3种HBsAg亚型的最低检出量性能进行评价.方法:用WHO HBsAg标准品,应用平行线终点稀释方法进行定量标定5份血浆样品HBsAg浓度;以浓度值大于5x l04IU/ml的样品,评价试剂的有效检测范围;以浓度值在5.9-100IU/ml范围内的样品,评价试剂的定量准确性;检测3种HBsAg亚型样品,